Boehringer Ingelheim

A ballpoint pen rests on top of a stack of documents ready for signing

Boehringer continues kidney dealmaking with $120M Variant pact

Boehringer unveiled its second kidney-focused collab in recent weeks, this time penning a deal worth up to $120 million with genomics-focused Variant.

James Waldron Jan 6, 2026 10:45am

pay deal hand over cash licensing transaction money

Boehringer spells out a $448M future for Rectify's ABC program

Dec 22, 2025 9:45am

2 pharmas turn Scrooge, returning biotechs' unwanted gifts

Dec 19, 2025 10:44am

pivot change turnaround direction walk away

Boehringer cuts ties to Nxera's phase 2-ready schizophrenia drug

Dec 19, 2025 6:35am

reshuffle pipeline target reorganize shift change

Ose narrows focus to conserve cash at expense of wider pipeline

Dec 9, 2025 9:41am

Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist

Nov 13, 2025 9:52am